Teva Pharmaceuticals
TEVA
507 hedge funds and large institutions have $11.5B invested in Teva Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 131 increasing their positions, 190 reducing their positions, and 64 closing their positions.
7.85% more ownership
Funds ownership: 58.39% → 66.24% (+7.8%)
5% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 64
2% more capital invested
Capital invested by funds: $11.2B → $11.5B (+$274M)
0% less funds holding
Funds holding: 508 → 507 (-1)
23% less funds holding in top 10
Funds holding in top 10: 13 → 10 (-3)
31% less repeat investments, than reductions
Existing positions increased: 131 | Existing positions reduced: 190
34% less call options, than puts
Call options by funds: $401M | Put options by funds: $612M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$662M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$447M |
| 3 |
Berkshire Hathaway
Omaha,
Nebraska
|
+$423M |
| 4 |
JP Morgan Chase
New York
|
+$352M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$75.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$178M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$124M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$97.7M |
| 4 |
Millennium Management
New York
|
-$56.4M |
| 5 |
Morgan Stanley
New York
|
-$50.6M |
TEVA Hedge Fund Activity: Q1 2018 in Review
507 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2018, worth a combined $11.5B — up 2.4% from $11.2B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new TEVA positions and 64 closed out — a net gain of 3 holders — while 131 added to existing stakes and 190 trimmed.
The largest buyer was Capital World Investors, adding an estimated $662M. The largest seller was Wellington Management Group, cutting an estimated $178M.
- 507 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2018, down from 508 in Q4 2017.
- Funds reported $11.5B of Teva Pharmaceuticals stock for Q1 2018, up 2.4% quarter-over-quarter.
- 67 funds opened new Teva Pharmaceuticals positions in Q1 2018 and 64 closed out, a net change of +3 holders.
- The largest Teva Pharmaceuticals buyer in Q1 2018 was Capital World Investors, an estimated $662M added.
- The largest Teva Pharmaceuticals seller in Q1 2018 was Wellington Management Group, an estimated $178M sold.
Based on aggregated 13F filings for Q1 2018.